Hepcidin and multiple myeloma related anemia

Medical Hypotheses

Volumn 66, Issue 2, 2006, Pages 352-354

  Cucuianu, Andrei ^a   Patiu, Mariana ^a   Rusu, Anca ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELL RECEPTOR; FERROPORTIN 1; HEPCIDIN; IMMUNOGLOBULIN; INTERLEUKIN 6; IRON;

ANEMIA; B LYMPHOCYTE; BACTERIAL INFECTION; BIOLOGICAL TRAIT; BLOOD TRANSFUSION; BONE ATROPHY; BONE MARROW; CANCER CELL; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; INTESTINE CELL; KIDNEY FAILURE; LIVER; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE; MULTIPLE MYELOMA; MYELOMA CELL; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECURRENT DISEASE; REVIEW; TRANSCRIPTION REGULATION; UPREGULATION;

BACTERIA (MICROORGANISMS);

EID: 28844481477     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.08.041     Document Type: Article

References (17)

1. S. Barille, R. Bataille, and M. Amiot The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma Eur Cytokine Netw 11 2000 546 551
2. V.M. Lauta A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications Cancer 97 2003 2440 2452
3. H.C. Blair, and N.A. Athanasou Recent advances in osteoclast biology and pathological bone resorption Histol Histopathol 19 2004 189 199
4. M. Mittelman The implications of anemia in multiple myeloma Clin Lymphoma 4 Suppl. 1 2003 S23 S29
5. F. Silvestris, M. Tucci, C. Quatraro, and F. Dammacco Recent advances in understanding the pathogenesis of anemia in multiple myeloma Int J Hematol 78 2003 121 125
6. W. Linkesch, and H. Ludwig Serum ferritin and beta 2-microglobulin in patients with multiple myeloma Cancer Detect Prev 6 1983 297 301
7. J.L. Spivak Iron and the anemia of chronic disease Oncology (Williston Park) 16 2002 25 33
8. Y. Beguin Erythropoiesis and erythropoietin in multiple myeloma Leuk Lymphoma 18 5-6 1995 413 421
9. E. Nemeth, S. Rivera, and V. Gabayan IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin J Clin Invest 113 2004 1271 1276
10. E. Nemeth, M.S. Tuttle, and J. Powelson Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization Science 306 2004 2051 2053
11. T. Ganz The role of hepcidin in iron sequestration during infections and in the pathogenesis of anemia of chronic disease Isr Med Assoc J 4 2002 1043 1045
12. M.A. Thompson, T.E. Witzig, and S. Kumar Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma Br J Haematol 123 2003 305 308
13. F.A. Mahmoud, and N.I. Rivera The role of C-reactive protein as a prognostic indicator in advanced cancer Curr Oncol Rep 4 2002 250 255
14. Pelliniemi TT, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995;85:765-771.
15. Kemna E, Tjalsma H, Laarakkers C, et al. A novel hepcidin assay by mass spectrometry. Blood. 2005 [Epub ahead of print].
16. M. Cucuianu, L. Plesca, and G. Bodizs Acute phase reaction and the hemostatic balance Rom J Intern Med 34 1996 13 18
17. E.L. Altschuler, and R.E. Kast Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression Med Hypotheses 65 2005 65 67